| Leo Pharma announces 'weapon' against psoriasis management | Posted on 29/09/2008 in Pharmaceutical Company Product News Leo Pharma has unveiled its new "weapon" in its ongoing campaign to improve the management of psoriasis and treatment outcomes for patients with the condition.
The firm unveiled its breakthrough at the conference of the European Academy of Dermatology and Venerology.
It described it as a "groundbreaking" computer-modelling tool that aims to help those involved in the assessment, planning and provision of treatment for the disease in primary care.
The tool has been designed to balance the increasing need for cost control with optimum patient outcomes.
Dubbed Psoriasis and Me, the resources simulates the use of a range of topical psoriasis drugs on costs and patient outcomes in a given primary care setting.
Peter Jackson, commercial development manager for Leo UK, said: "Health economics is an increasingly important factor in service redesign but it is often seen as a cold discipline that works against patient needs."
He added the Psoriasis and Me programme shows this does not have to be the case.
In August 2008, Leo Pharma nnounced the approval of Xamiol in Europe for the treatment of psoriasis, with the compound due to be launched in the fourth quarter of this year.Other news stories from 29/09/2008
Read more in the Zenopa News Archive
How this news is generated
|  |
|
